FCMI
Foresite Capital Management III Portfolio holdings
AUM
$37.9M
This Quarter Return
+124.84%
1 Year Return
-6.87%
3 Year Return
+443.49%
5 Year Return
+535.97%
10 Year Return
–
AUM
$114M
AUM Growth
+$114M
(+32%)
Cap. Flow
+$903K
Cap. Flow
% of AUM
0.79%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
1
Reduced
–
Closed
1
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$9.29M |
| 2 |
Aclaris Therapeutics
ACRS
|
$8.43M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Aclaris Therapeutics
ACRS
$209M
| $49.3M | 43.26% | 1,954,904 +334,660 | +21% | +$8.43M |
|
|
XLRN
2
DELISTED
Acceleron Pharma Inc.
XLRN
| $14.7M | 12.94% | 108,630 | – | – |
|
3
Natera
NTRA
$23.1B
| $12.9M | 11.35% | 127,305 | – | – |
|
4
FibroGen
FGEN
$47.8M
| $10.6M | 9.32% | 305,784 | – | – |
|
|
VRNA
5
Verona Pharma
VRNA
$9.16B
| $9.29M | 8.16% | +1,111,112 | New | +$9.29M |
|
|
EPZM
6
DELISTED
Epizyme, Inc
EPZM
| $8.7M | 7.64% | 998,278 | – | – |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $7.45M | 6.55% | 1,641,804 | – | – |
|
8
Novavax
NVAX
$1.21B
| $907K | 0.8% | 5,000 | – | – |
|